Search Results

You are looking at 81 - 90 of 176 items for :

  • "cetuximab" x
  • All content x
Clear All
Full access

Hans F. Schoellhammer, Gagandeep Singh, and Lucille Leong

resectability after a mean 10 cycles of chemotherapy. Rates of 5- and 10-year survival for the surgery group were 33% and 23%, respectively. Multiple trials have shown that the addition of targeted antibody agents to chemotherapy, such as cetuximab (an anti

Full access

Keith D. Eaton and Renato G. Martins

9 and the anti-EGFR antibody cetuximab 10 have improved survival when combined with first-line chemotherapy. In an effort to improve the results of first-line chemotherapy, the concept of maintenance therapy has been tested in NSCLC ( Table

Full access

David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara A. Burtness, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr., Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, Giuseppe Sanguineti, David E. Schuller, Jatin P. Shah, Sharon Spencer, Andy Trotti III, Randal S. Weber, Gregory T. Wolf, and Frank Worden

agreed that many different alternatives are reasonable (including concurrent low-dose weekly cisplatin, weekly taxanes, cetuximab, or combinations thereof), but are inadequately studied, to be specifically recommended. 168 After induction chemotherapy

Full access

Scott Ramsey and Veena Shankaran

responsiveness to the anti–epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab. 9 , 10 Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), has also been shown to improve survival in the first

Full access

Leora Horn

single-agent cetuximab, although the latter agent is rarely used. “ECOG 4599 was the first continuation maintenance therapy trial where we saw a survival benefit,” said Dr. Horn. Sandler et al 3 found that the addition of bevacizumab to paclitaxel plus

Full access

Peyman Haghighat and Tanios Bekaii-Saab

. Cancer 1995 ; 75 : 1418 – 1425 . 38. Pinto C Di Fabio F Siena S . Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) . Ann Oncol

Full access

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda

BRAF mutations in CRC has led to mostly disappointing results, 15 , 16 prompting further studies 17 and alternative treatment strategies. In one recently reported phase II study, treatment with vemurafenib in combination with cetuximab and irinotecan

Full access

Philip E. Lammers, Christine M. Lovly, and Leora Horn

further genetic testing. The patient subsequently enrolled in a phase I/II clinical trial evaluating the combination of afatinib, 40 mg daily, and cetuximab, 500 mg/m 2 , every 2 weeks in patients with EGFR -mutant lung cancer with acquired resistance

Full access

Margaret Tempero

pathways also showed improved survival and a lower rate of chemotherapy-related admissions. 2 Regarding cost, when efficacy is similar, such as with cetuximab and panitumumab, giving the less expensive option in the pathway can save a lot of money. 3

Full access

Harold J. Burstein

cetuximab after prior epidermal growth factor receptor (EGFR) inhibitor treatment. Despite the NCCN Guidelines admonitions, many patients received non-recommended treatments (10% received bevacizumab, 16% inhibitors, and 49% capecitabine). Costs for these